The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC).
Michael J. Morris
No relevant relationships to disclose
Neeta Pandit-Taskar
No relevant relationships to disclose
Jorge A. Carrasquillo
No relevant relationships to disclose
Joseph A. O' Donoghue
No relevant relationships to disclose
John Humm
No relevant relationships to disclose
Serge K. Lyashchenko
No relevant relationships to disclose
Eric C. Haupt
No relevant relationships to disclose
Neil Harrison Bander
No relevant relationships to disclose
Scott T. Tagawa
No relevant relationships to disclose
Jason P. Holland
No relevant relationships to disclose
Peter M. Smith-Jones
No relevant relationships to disclose
Jason Stuart Lewis
No relevant relationships to disclose
Stephen Barnett Solomon
No relevant relationships to disclose
Howard I. Scher
No relevant relationships to disclose
Steven M. Larson
No relevant relationships to disclose